Additional Metadata
Persistent URL dx.doi.org/10.1093/annonc/mdy279.400, hdl.handle.net/1765/125541
Journal Annals of Oncology
Citation
Melero, I. (I.), Castanon Alvarez, E. (E.), Mau-Sorensen, M. (M.), Lassen, U, Lolkema, M.P, Robbrecht, D.G. (D. G.), … Schellens, J.H.M. (2018). Clinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v). Annals of Oncology, 29, viii134–viii135. doi:10.1093/annonc/mdy279.400